22 KB148 KB14 KB199220252004Banev, SašoIlievska Poposka, BiljanaPetrusevska, GordanaSmickova, SnežanaSpirovski, Zoranštevilka:2letnik:385 stranistr. 131-135ISSN:1318-2099COBISSID:18167257URN:URN:NBN:SI:doc-CMNATRE5enAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)biokemijadiagnostikaImmunohistochemistryImunohistokemijaLung NeoplasmsNeoplasm StagingNovotvorba, stadijnovotvorbePathologyPljučne novotvorbepljučni rakPrognosisPrognozaproteiniProto-Oncogene Proteins C-Erbb-2tumorImmunohistochemical expression of HER-2/neu in patients with lung carcinoma and its prognostic significance|Background. The HER-2 protein or p185her2 is a membrane receptor with tyrosinekinase activity encoded by HER-2/neu gene. Overexpression of HER-2/neuhas been observed in many human cancers, including lung cancer. In the study, the expression of HER-2 protein is determined in the spectrum of lung cancer (adenocarcinoma, sguamous cell carcinoma and small cell carcinoma). Patients and methods. The study population consisted of two groups: 19 patients that had undergone surgical treatment and 10 patients thathad undergone fiber-optic bronchoscopy and biopsy for primary diagnosis only. Tissue specimens were neutral formaldehyde fixed and paraffin-embedded. Standard histochemical and immunohistochemical staining were used for diagnosis. Expression of HER-2/neu protein was determined by immunohistochemical staining with Hercep TestT`` (DAKO). The results were graded 0-1 as negative and 2-3 as positive. Results. Overall incidence of HER-2/neu overexpression was 34.4% (10 of 29). Higher incidence was found in the patients with adenocarcinoma 45.4% (5 of 11). In squamous cell carcinoma and small cell carcinoma, the overexpression incidence was 30.7% (4 of 13) and20% (1 of 5), respectively. No statistically significant difference was seen given the age and gender. HER-2/neu overexpression was more pronounced inthe patients with advanced tumour: all patients with squamous cell carcinomaand HER-2/neu overexpression had stage IIIB and stage IV disease, while 80% of adenocarcinoma patients with HER-2/neu overexpression had stage IIIA and IIIB disease. Conclusions. These results are satisfactory and encourage us to continue this work in the follow-up study to evaluate HER-2/neu role as predictive and prognostic factor for the patients with lung cancerIzhodišča. Protein HER-2 ali p185her2 je membranski receptor s tirozinsko kinazno aktivnostjo, ki je določena z genom HER-2/neu. Prekomerno aktivnost HER-2/neu lahko zasledimo pri bolnikih z različnimi onkološkimi obolenji, takotudi pri raku pljuč. Ker obstajajo različna poročila o stopnji aktivnosti tega gena pri pljučnem raku, smo v raziskavi določali protein HER-2 pri bolnikih z žleznim, skvamoznoceličnim in drobnoceličnim pljučnim rakom. Bolniki in metode. Protein HER-2 smo določali pri tumorjih 29 bolnikov s pljučnim rakom; 19 bolnikov je bilo operiranih, pri 10 pa smo tumorsko tkivo dobili ob diagnostičnem postopku z upogljivim bronhoskopom preden smo jih zdravili s kemo/radioterapijo. Vzorce tkiva smo fiksirali v nevtralnem formalinu in naredili parafinske preparate. Za diagnosticiranje smo uporabljali standardna histokemična in imunohistokemična barvanja. Prisotnost proteina HER-2/neu smo potrjevali z imunohistokemičnim barvilom s pomočjo Hercep Testa (DAKO). Rezultate testiranja smo označili s stopnjami od 0 do 3. Stopnjo 0 in 1 smo ocenili kot negativno, s stopnjo 2 ali 3 pa kot pozitivno. Rezultati. Prekomerno izraženost proteina HER-2/neu smo zasledili v 34,4% (pri10 od 29 bolnikov). V večji meri smo ga ugotovili pri bolnikih z žleznim rakom in to v 45,4% (pri 5 od 11 bolnikov), pri bolnikih s skvamoznoceličnim rakom pa v 30,7% (4 od 13 bolnikov) in pri bolnikih z drobnoceličnim rakom le v 20% (1 od 5 bolnikov). Glede na starost in spol nismo našli statistično značilnih razlik. Pri napredovalih oblikah bolezni smo ugotovili večjo izraženost proteina HER2/neu, saj so imeli vsi bolniki s skvamoznoceličnim rakom pljuč in stadijem bolezni IIIB in IV povišan protein, bolniki z žleznim karcinomom in stadijem IIIB in IV pa v 80%. Zaključki. Obetajoči rezultati kažejo, da bi lahko imel HER-2/neu pri bolnikih s pljučnim rakom prediktivni in prognostični pomen, kar bomo poskusili potrditi po daljšem spremljanju bolnikovTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaDruštvo radiologije in onkologije